Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Biochem. 2012 Nov;45(16-17):1389-93. doi: 10.1016/j.clinbiochem.2012.06.026. Epub 2012 Jul 1.

The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients.

Author information

  • 1Institute of BioMedical Nutrition, Hungkuang University, Taiwan. chiouyl@sunrise.hk.edu.tw

Abstract

BACKGROUND/AIM:

Chronic hepatitis C (CHC) patients have higher oxidative stress and ferritin than healthy individuals. However, the level of oxidative stress in CHC patients during treatment with peginterferon alpha-2a and ribavirin is not clear. The aims of our study are to investigate changes of thiobarbituric acid reactive substances (TBARS; indicated oxidative stress), total antioxidant status (TAS) and ferritin in CHC patients during therapy and to identify the correlation of these factors and the effectiveness of therapy.

METHODS:

Sixty CHC patients were selected and were prescribed 180 μg of peginteferon alpha-2a once a week and a daily dose of 1000 to 1200 mg ribavirin for 6 months. Throughout the treatment course, blood samples were taken to determine TBARS, TAS, and liver inflammation profiles including ferritin, aspartate transaminase (AST) and alanine transaminase (ALT).

RESULTS:

The level of TBARS increased before the 12th week of therapy. Additionally, the levels of TBARS were higher in non-rapid virological response (RVR) patients compared with RVR (p<0.01) in baseline and therapy at the 24th week. TAS was lower during therapy than at baseline. Levels of TAS were significantly higher in sustained virological response (SVR) patients than in non-SVR (p<0.01) in the 4th week post-therapy. We also found a positive correlation between the level of ferritin and liver inflammation during treatment (p<0.01). The levels of ferritin and ALT were lower in SVR than in non-SVR patients in the 4th week of post-therapy (p<0.01).

CONCLUSIONS:

This study indicated that decreased ferritin, decreased TBARS and increased TAS status may improve the efficacy of treatment.

Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PMID:
22760008
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk